Giovanella Luca, Ceriani Luca, Ghelfo Antonella, Keller Franco
Division of Nuclear Medicine and Thyroid Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Clin Chem Lab Med. 2005;43(8):843-7. doi: 10.1515/CCLM.2005.142.
Thyroidectomy followed by administration of large activities of 131I is the treatment of choice for differentiated thyroid carcinomas. Due to its good prognosis, some authors argue that papillary thyroid cancer with a diameter of up to 10 mm can be treated by surgery alone. In the new TNM classification started in 2002, the T1 group now encompasses all tumours with a diameter up to 20 mm, which widens the indications for a conservative approach. In this instance, prognostic markers are needed to better select patients before planning non-aggressive treatment. Serum thyroglobulin plays a pivotal role in thyroid carcinoma management after thyroid ablation (i.e., surgery and radioiodine) but is of limited value before these treatments. However, thyroglobulin assay performed after surgery but before radioiodine treatment has been proven to be useful in predicting the presence/absence of distant metastasis.
Our study was undertaken in patients affected by pT1 papillary thyroid carcinoma to evaluate the predictive value of post-surgery thyroglobulin assay on 1) restaging immediately after radioiodine treatment and 2) restaging at 12 months. We selected 156 patients affected by pT1 histologically proven papillary thyroid carcinoma, submitted to total thyroidectomy. Serum thyroglobulin was assayed by a specific immunoradiometric method 4 weeks after surgery, just before radioiodine administration. Cut-off levels were selected by receiver operating characteristic curve analysis. Thyroglobulin levels were compared to the results of a post-radioiodine treatment scan and 12-month restaging.
Globally, 23 out of 156 patients showed persistent/recurrent disease (15%). Post-surgery thyroglobulin levels above 4.50 microg/L identified 94% of patients with metastasis at post-dose scan, and a level below 3.20 microg/L identified 86% and 93% of relapsed and disease-free patients at 12-month restaging, respectively. Multivariate analysis and Spearman rank correlation showed that the N-status and post-surgery thyroglobulin level are independent prognostic factors.
The post-surgery thyroglobulin level could be systematically assayed in patients with pT1-papillary thyroid carcinoma and taken into account in planning treatment.
甲状腺切除术后给予大剂量的131I是分化型甲状腺癌的首选治疗方法。由于其预后良好,一些作者认为直径达10mm的甲状腺乳头状癌可仅通过手术治疗。在2002年开始的新TNM分类中,T1组现涵盖所有直径达20mm的肿瘤,这拓宽了保守治疗的适应证。在这种情况下,需要预后标志物以便在规划非侵袭性治疗前更好地选择患者。血清甲状腺球蛋白在甲状腺消融(即手术和放射性碘)后的甲状腺癌管理中起关键作用,但在这些治疗前价值有限。然而,手术后但在放射性碘治疗前进行的甲状腺球蛋白检测已被证明对预测远处转移的有无有用。
我们对受pT1期甲状腺乳头状癌影响的患者进行了研究,以评估术后甲状腺球蛋白检测对1)放射性碘治疗后立即重新分期和2)12个月时重新分期的预测价值。我们选择了156例经组织学证实为pT1期甲状腺乳头状癌并接受全甲状腺切除术的患者。术后4周,即在给予放射性碘前,通过特定的免疫放射分析方法检测血清甲状腺球蛋白。通过受试者工作特征曲线分析选择临界值。将甲状腺球蛋白水平与放射性碘治疗后扫描结果及12个月重新分期结果进行比较。
总体而言,156例患者中有23例显示疾病持续/复发(15%)。术后甲状腺球蛋白水平高于4.50μg/L可识别出94%在给药后扫描时有转移的患者,而低于3.20μg/L的水平分别可识别出86%和93%在12个月重新分期时复发和无病的患者。多因素分析和Spearman等级相关性分析表明N分期和术后甲状腺球蛋白水平是独立的预后因素。
对于pT1期甲状腺乳头状癌患者,术后甲状腺球蛋白水平可进行系统检测,并在规划治疗时予以考虑。